SGLT2 Inhibition in Hemodialysis

Sponsor
Medical University of Vienna
Study ID
NCT05179668
Phase
PHASE2
Status
Completed

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • Dapagliflozin 10 MG — DRUG
    administered orally once daily
  • Placebo — DRUG
    administered orally once daily

Study Details

Dapagliflozin will be compared with placebo to evaluate its effects on cardiac structure and safety in patients with kidney failure receiving maintenance hemodialysis.

Key Dates

Start date
Oct 1, 2022
Status verified
Feb 2026
Primary completion
Jul 11, 2025
Completion
Feb 28, 2026

Study Design

Enrollment
220 participants (actual)
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT

Arms

  • Experimental: Dapagliflozin 10 mg
  • Placebo Comparator: Placebo tablet

Primary Outcome Measure

Change in left ventricular mass indexed to body surface area [ Time Frame: 6 months ]

Related Studies